Stakeholders agree to start Ebola vaccine efficacy trials December
This article was originally published in Scrip
Executive Summary
Efficacy trials of two experimental Ebola vaccines – one being developed by GlaxoSmithKline and the other by NewLink – should be launched in December in Africa rather than waiting for early 2015, as initially planned, a group of 90 high-level stakeholders from industry, government, academia and nonprofits concluded.